Ravindra Reddy, MD
Psychiatry · New Orleans, LANPI 1487679478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 464 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,488 and has fallen 60.7% since, to $585 in 2025. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$928
- Lundbeck LLC$786
- Takeda Pharmaceuticals U.S.A., Inc.$628
- Johnson & Johnson$504
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$431
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,00699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 139 | $1,551 |
| Otsuka America Pharmaceutical, Inc. | 57 | $928 |
| Lundbeck LLC | 45 | $786 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $628 |
| Johnson & Johnson | 31 | $504 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $431 |
| Sunovion Pharmaceuticals Inc. | 28 | $371 |
| Almatica Pharma LLC | 18 | $311 |
| Alkermes, Inc. | 14 | $281 |
| Shire North American Group Inc | 11 | $197 |
| Teva Pharmaceuticals USA, Inc. | 9 | $170 |
| Supernus Pharmaceuticals, Inc. | 6 | $160 |
| Vanda Pharmaceuticals Inc. | 7 | $140 |
| Axsome Therapeutics, Inc. | 7 | $126 |
| Corium, LLC | 9 | $118 |
| Tris Pharma Inc | 5 | $94 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Adlon Therapeutics L.p. | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Merck | 2 | $33 |
| Indivior Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$7,053 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 81 | $216,990 |
| Risperdal ConstaRisperidone Microspheres | 26 | $33,795 |
| RexultiBrexpiprazole | 13 | $20,527 |
| TrintellixVortioxetine Hydrobromide | 31 | $17,583 |
| VraylarCariprazine Hcl | 11 | $16,749 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $13,523 |
| Lurasidone Hcl | 58 | $5,746 |
| Quetiapine Fumarate | 440 | $5,744 |
| XanaxAlprazolam | 11 | $5,568 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 172 | $5,274 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $4,624 |
| Duloxetine Hcl | 245 | $4,615 |
| Lisdexamfetamine Dimesylate | 15 | $3,629 |
| Aripiprazole | 211 | $3,418 |
| Oxcarbazepine | 67 | $3,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $504 | $250,785107 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $628 | $31,10660 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $928 | $20,52713 claims |
| AbbVieVraylar | $1,551 | $16,74911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in New Orleans
- Arwen PodestaNew Orleans$466K
- Andrew MorsonNew Orleans$56K
- James BarbeeNew Orleans$28K
- Neha KansaraNew Orleans$13K
- Erich ConradNew Orleans$9K
- Rahn BaileyNew Orleans$8K
- Nick RamandiNew Orleans$8K
- Ashley WeissNew Orleans$8K
- Paul PeltsNew Orleans$6K
- Janet BradleyNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.